PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update

SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE^®"), today announced that it will release its 2021 fourth quarter financial results before the opening of the U.S. financial markets on Friday, March 11, 2022. Company executives will host a conference call at 8:30am ET that day with institutional investors and analysts to provide an overview of PLx Pharma's performance for the quarter, along with a business update.

2021 Fourth Quarter Conference Call

A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 2664996. The archived webcast will be available via PLx Pharma's investor relations website for 30 days after the call.

About VAZALORE

VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule is designed for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin. To learn more about VAZALORE, please visit www.vazalore.com.

About PLx Pharma Inc.

PLx Pharma Inc. is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ technology. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach injury associated with certain drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Contacts:

Janet M. Barth

Vice President, Investor Relations & Corporate Communications, PLx Pharma Inc.

(973) 409-6542

[email protected] 

Lisa M. Wilson

Founder & President, In-Site Communications, Inc.

T: 212-452-2793

E: [email protected]